- September 15, 2020
- Posted by: The Quaternary Sector
- Category: News
No Comments

As most manufacturers experienced firsthand, operating during a pandemic is challenging. Pfizer manufactures more than 23 billion doses of biopharmaceutical products – ranging from solid oral doses to vaccines and sterile injectables – across a network of 42 global manufacturing sites. Accomplishing this task during a pandemic intensified the […]
Click here to view original web page at www.industryweek.com
Leave a Reply
You must be logged in to post a comment.